Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Jahr

2018

Autoren

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.

Verlag

Lancet. 2018 Mar 31;391(10127):1263-1273. Epub 2018 Mar 23.

Link

https://doi.org/10.1016/s0140-6736(18)30475-6

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Long-term effects of siponimod on cardiovascular and autonomic nervous system in secondary progressive multiple sclerosis

COVID-19 and multiple sclerosis: challenges and lessons for patient care

A future of AI-driven personalized care for people with multiple sclerosis

Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons

Evaluation of therapy satisfaction with cladribine tablets in patients with RMS: Final results of the non-interventional study CLEVER